



March Formulary Update

Effective March 24, 2023

New Formulary Medications:

- a. amoxicillin-clavulanate injection

Formulary Restricted Medication Amendments:

- a. ondansetron orally disintegrating tablets (ODT): restriction updated to patients unable to receive other ondansetron oral solids or injectable ondansetron (e.g. patients without IV access)

Formulary Restricted Medications:

- a. BC Cancer: addition of following medications restricted to indications outlined in the BC Cancer Benefit Drug List and patients who are registered with BC Cancer
 - azacitidine (Onureg®) oral tablet
 - bevacizumab (Aybintio®) injection (biosimilar brand)
 - daunorubicin liposomal-cytarabine liposomal (Vyxeos®) injection
 - fedratinib (Inrebic®) oral capsule
 - trastuzumab (Ontruzan®) injection (biosimilar brand)
- b. BCCDC: addition of following vaccine restricted to the publicly funded indications outlined in the BCCDC Communicable Disease Control Manual
 - COVID-19 (Moderna®) bivalent vaccine

Therapeutic Equivalency Decision:

- a. sumatriptan oral tablet and sumatriptan DF (dissolve faster) tablet will be listed on the BC hospital formulary as equivalent

Discontinued Medications:

- a. attapulgit (Kaopectate®) oral suspension
- b. dimercaprol (Bal-In-Oil®) injection
- c. metronidazole (Metro lotion®) topical lotion
- d. nystatin (Nyaderm®) topical ointment
- e. sulfamethoxazole-trimethoprim (Cotrimoxazole®) oral suspension

March 24, 2023 For the information of physicians, nurses, and pharmacists. PLEASE POST	Formulary Changes	✓	For further information contact: <i>Jessica Granberg</i> Medication Use Management Pharmacists mumpharmacist@northernhealth.ca
	Drug Discontinuation		
	Medication Change		